XML 51 R17.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Equity | 6 Months Ended
--- | ---
Jun. 30, 2018
Equity [Abstract] |
Equity | Equity Total equity as of June 30, 2018, decreased $344.4 million compared to December 31, 2017. This decrease was primarily due to share repurchases totaling $3.0 billion, as described below, partially offset by net income attributable to Biogen Inc. of approximately $2.0 billion and a net cumulative-effect adjustment of approximately $0.5 billion recognized to retained earnings upon the adoptions of ASUs 2016-16 and 2016-01. For additional information related to the adoption of ASUs 2016-16 and 2016-01, please read Note 1, Summary of Significant Accounting Policies, to these condensed consolidated financial statements. Share Repurchases In July 2016 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (2016 Share Repurchase Program), which was completed as of June 30, 2018. Under our 2016 Share Repurchase Program, we repurchased and retired 9.6 million and 10.5 million shares of our common stock at a cost of $2.75 billion and $3.0 billion during the three and six months ended June 30, 2018, respectively, and we repurchased and retired 2.9 million and 3.7 million shares of our common stock at a cost of $781.8 million and $1.0 billion during the three and six months ended June 30, 2017, respectively. In February 2011 our Board of Directors authorized a program to repurchase up to 20.0 million shares of our common stock (2011 Share Repurchase Program). Shares repurchased under our 2011 Share Repurchase Program were principally used to offset common stock issuances under our share-based compensation programs. Our 2011 Share Repurchase Program was completed as of March 31, 2017. Under our 2011 Share Repurchase Program, we repurchased 1.3 million shares of our common stock at a cost of $365.4 million during the six months ended June 30, 2017. Noncontrolling Interests The following table reconciles equity (deficit) attributable to noncontrolling interests (NCI):
| For the Three Months Ended June 30, |  | For the Six Months Ended June 30,
(In millions) | 2018 |  | 2017 |  | 2018 |  | 2017
NCI, beginning of period | $ | (16.2 | ) |  | $ | (11.6 | ) |  | $ | (14.7 | ) |  | $ | (11.5 | )
Net income (loss) attributable to NCI, net of tax | 48.4 |  |  | — |  |  | 46.7 |  |  | (0.1 | )
Capital contribution by noncontrolling interest | 11.1 |  |  | — |  |  | 11.1 |  |  | — |
Distribution to noncontrolling interest | (50.0 | ) |  | — |  |  | (50.0 | ) |  | — |
Translation adjustment and other | (0.5 | ) |  | — |  |  | (0.3 | ) |  | — |
NCI, end of period | $ | (7.2 | ) |  | $ | (11.6 | ) |  | $ | (7.2 | ) |  | $ | (11.6 | )

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration